Erythrocine oral ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
36Epidermolysis bullosa1

36. Epidermolysis bullosa


Clinical trials : 160 Drugs : 195 - (DrugBank : 47) / Drug target genes : 50 - Drug target pathways : 124
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-024428-10-FR
(EUCTR)
03/02/2011Traitement des épidermolyses bulleuses simples de type Dowling Maera par l'érythromicine oraleTraitement des épidermolyses bulleuses simples de type Dowling Maera par l'érythromicine orale Dowling Maera's bullous epidermolysis is a génodermatose with autosomique dominant transmission owed to transfers of the genes coding for keratins. It results from it a cutaneous fragility very severe especially during the early childhood. Tetracyclines showed a certain efficiency in cases isolated probably by their anti-inflammatory action but cannot be used at the young child's. The érythromycine, used in the other inflammatory dermatosis, seems to be a good candidate for these patients.
MedDRA version: 12.1;Level: LLT;Classification code 10056508;Term: Acquired epidermolysis bullosa
Trade Name: erythrocine
Product Name: erythrocine oral
Trade Name: erythromycine
Product Name: erythrocine oral
CHU de NICENULLNAFemale: yes
Male: yes
8Phase 2France